Entering text into the input field will update the search result below

Agilent's PD-L1 IHC 28-8 pharmDx gets CE-IVD mark approval

Electronics Firm Agilent To Sell Chip Unit For $2.66 Billion

Justin Sullivan/Getty Images News

  • Agilent Technologies (NYSE:A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.
  • PD-L1

Recommended For You

More Trending News

About A Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
A--
Agilent Technologies, Inc.